

NephroGenex, Inc.  
Form S-1MEF  
July 16, 2015

As filed with the Securities and Exchange Commission on July 16, 2015

Registration No. 333-

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM S-1**

**REGISTRATION STATEMENT**

**UNDER**

**THE SECURITIES ACT OF 1933**

---

**NephroGenex, Inc.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**20-1295171**  
(I.R.S. Employer  
Identification Number)

**3200 Beechleaf Court**  
**Suite 900**  
**Raleigh, NC 27604**  
**(609) 986-1780**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Edgar Filing: NephroGenex, Inc. - Form S-1MEF

---

**Pierre Legault**  
**Chief Executive Officer**  
**NephroGenex, Inc.**  
**3200 Beechleaf Court**  
**Suite 900**  
**Raleigh, NC 27604**  
**(609) 986-1780**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

---

**Copies to:**

**Joel I. Papernik, Esq.**  
**Kenneth R. Koch, Esq.**  
**Daniel A. Bagliebter, Esq.**  
Mintz, Levin, Cohn, Ferris,  
Glovsky and Popeo, P.C.  
666 Third Avenue New York, NY 10017  
(212) 935-3000

**Yvan-Claude Pierre, Esq.**  
**William Haddad, Esq.**  
Reed Smith LLP  
599 Lexington Avenue  
New York, New York 10022  
(212) 521-5400  
(212) 521-5450 Facsimile

---

**Approximate date of commencement of proposed sale to the public: From time to time after this Registration Statement becomes effective.**

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: "

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: "

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. x 333-203530

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. "

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. "

## Edgar Filing: NephroGenex, Inc. - Form S-1MEF

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. "

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one).

company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer	..		Accelerated filer	..
Non-accelerated filer	..	(Do not check if a smaller reporting company)	Smaller reporting company	x

### CALCULATION OF REGISTRATION FEE

Title of each class of securities to be registered	Proposed maximum aggregate offering price(1)(2)	Amount of Registration fee(2)(3)
Common Stock, \$0.001 par value per share	\$ 1,437,500	\$ 167.04
Warrants to purchase shares of common stock		
Shares of common stock issuable upon the exercise of the warrants	\$ 1,796,875	\$ 208.80
<b>Total</b>	<b>\$ 3,234,375</b>	<b>\$ 375.84</b>

- (1) This Registration Statement relates to the Registrant's Registration Statement on Form S-1 (File No. 333-203530), which was declared effective by the Securities and Exchange Commission (the SEC) on July 16, 2015 (the Prior Registration Statement). In accordance with Rule 462(b) under the Securities Act of 1933, as amended, the proposed maximum offering price of the remaining securities eligible to be sold under the Prior Registration Statement (\$16,171,875) is carried forward to this Registration Statement and an additional amount of securities having a proposed maximum aggregate offering price of no more than 20% thereof, or \$3,234,375, is registered hereby, which includes shares issuable upon exercise of the underwriters' over-allotment option.
- (2) Estimated solely for the purposes of computing the amount of the registration fee in accordance with Rule 457(o) promulgated under the Securities Act of 1933, as amended.
- (3) Previously paid.

**This Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) of the Securities Act of 1933, as amended.**

**EXPLANATORY NOTE AND INCORPORATION BY REFERENCE**

This registration statement is being filed with respect to the registration of additional shares of common stock, par value \$0.001 per share, of NephroGenex, Inc., a Delaware corporation, warrants to purchase shares of common stock and shares of common stock issuable upon exercise of the warrants, pursuant to Rule 462(b) under the Securities Act of 1933, as amended. The contents of the earlier registration statement on Form S-1 (File No. 333-203530), which was declared effective by the SEC on July 16, 2015 are incorporated in this registration statement by reference.

The required opinions and consents are listed on an Exhibit Index attached hereto and filed herewith.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Raleigh, State of North Carolina, on July 16, 2015.

NEPHROGENEX, INC.

By: */s/ Pierre Legault*  
 Pierre Legault  
*Chief Executive Officer*

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
<i>/s/ Pierre Legault</i> Pierre Legault	Chief Executive Officer and Director <i>(Principal Executive Officer)</i>	July 16, 2015
<i>/s/ John P. Hamill</i> John P. Hamill	Chief Financial Officer <i>(Principal Financial Officer and Principal Accounting Officer)</i>	July 16, 2015
* Richard Markham	Chairman of the Board of Directors	July 16, 2015
* James Mitchum	Director	July 16, 2015
* Robert R. Seltzer	Director	July 16, 2015
* Eugen Steiner, M.D.	Director	July 16, 2015
* Marco Taglietti, M.D.	Director	July 16, 2015
*By: <i>/s/ Pierre Legault</i> Pierre Legault, Attorney-in-fact		July 16, 2015

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
5.1	Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, with respect to the legality of securities being registered.
23.1	Consent of EisnerAmper LLP, independent registered public accounting firm.
23.2	Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C (included in Exhibit 5.1).
24.1	Power of Attorney (incorporated by reference to Exhibit 24.1 to the Company's Registration Statement on Form S-1, filed with the Securities and Exchange Commission on April 20, 2015).